Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It
CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects. Viking is testing whether VK2735 can shift patients from weekly weight-loss injections to monthly maintenance dosing. The completed study tested every-other-week doses up to 10 mg and monthly doses reaching 22.5 mg; results remain due this quarter. … Read more